ClinVar Miner

Submissions for variant NM_000518.5(HBB):c.3G>A (p.Met1Ile)

dbSNP: rs33930702
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000508308 SCV000601303 pathogenic not provided 2017-02-06 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000506641 SCV000603948 pathogenic not specified 2017-02-04 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002222353 SCV002500547 pathogenic Dominant beta-thalassemia 2022-03-21 criteria provided, single submitter clinical testing Variant summary: HBB c.3G>A alters the initiation codon (therefore the predicted protein level name is p.Met1Ile) and is expected to result either in absence of the protein or truncation of the encoded protein due to translation initiation at a downstream codon. The variant was absent in 251128 control chromosomes (gnomAD). c.3G>A has been reported in the literature in multiple individuals in the heterozygous state, who had hematologic findings characteristic for Beta Thalassemia Minor (Saba_1991, Landin_1995, Vetter_1997), in addition, one of the reported heterozygous individuals had child(ren) with transfusion-dependent thalassemia (Hussain_2017). These data indicate that the variant in homozygosity and/or compound heterozygosity with a severe variant, is likely to cause the BTHAL MJR phenotype. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Other variants affecting the initiation codon (e.g. c.1A>G, c.2T>G, c.2T>C) have been classified as pathogenic by our laboratory. Three submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and all classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
OMIM RCV000016783 SCV000037053 pathogenic Beta zero thalassemia 1993-06-01 no assertion criteria provided literature only
The ITHANET community portal, The Cyprus Institute of Neurology and Genetics RCV001078376 SCV001244574 pathogenic beta Thalassemia 2019-11-25 no assertion criteria provided curation

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.